AU Patent

AU2025210778A1 — Dry pharmaceutical formulations of CNP conjugates

Assigned to Ascendis Pharma Endocrinology Division AS · Expires 2025-09-11 · 1y expired

What this patent protects

#$%^&*AU2025210778A120250911.pdf##### Abstract A dry pharmaceutical formulation, wherein the pharmaceutical formulation comprises a CNP conjugate, a buffering agent and a bulking agent and wherein the CNP conjugate comprises a CNP moiety that is covalently and reversibly co…

USPTO Abstract

#$%^&*AU2025210778A120250911.pdf##### Abstract A dry pharmaceutical formulation, wherein the pharmaceutical formulation comprises a CNP conjugate, a buffering agent and a bulking agent and wherein the CNP conjugate comprises a CNP moiety that is covalently and reversibly conjugated to a polymeric moiety. Abstract A dry pharmaceutical formulation, wherein the pharmaceutical formulation comprises a CNP conjugate, a buffering agent and a bulking agent and wherein the CNP conjugate comprises a CNP moiety that is covalently and reversibly conjugated to a polymeric moiety.

Drugs covered by this patent

Patent Metadata

Patent number
AU2025210778A1
Jurisdiction
AU
Classification
—
Expires
2025-09-11
Drug substance claim
No
Drug product claim
No
Assignee
Ascendis Pharma Endocrinology Division AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.